Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
On August 5, 2025, Inspire issued a press release announcing better-than-expected second quarter fiscal 2025 results, but surprisingly also slashed its full-year guidance from anticipated earnings of $2.20 – $2.30 on revenue of $940m – $955m down to earnings of $0.40 – $0.50 on revenue of $900m – $910m. This follows Inspire raising its earnings guidance only one quarter ago. Management blamed the guidance setback on slowdowns related to the recent rollout of Inspire V. The company disclosed that the commercial rollout “encountered certain headwinds” such as centers failing to complete training and onboarding criteria, customer delays, technical Medicare adoption delays, and continued higher demand for Inspire IV devices.
Following this news, Inspire’s stock price fell by $46.44 per share to open at $83.51 per share.